133,009 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 133,009 shares of the biotechnology company’s stock, valued at approximately $2,658,000. State of Alaska Department of Revenue owned approximately 0.06% of ADMA Biologics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $29,000. EntryPoint Capital LLC bought a new stake in ADMA Biologics during the first quarter worth approximately $31,000. CWM LLC grew its position in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of ADMA Biologics in the second quarter valued at $93,000. Finally, USA Financial Formulas increased its holdings in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock valued at $8,224,121 in the last 90 days. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Trading Down 3.8 %

NASDAQ ADMA opened at $16.31 on Friday. The firm’s 50 day moving average price is $17.86 and its two-hundred day moving average price is $13.25. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics, Inc. has a twelve month low of $3.23 and a twelve month high of $21.13. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 116.50 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of ADMA Biologics in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.